Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer.
Archana M AgarwalRoberto H NussenzveigAndrew W HahnJohn M HoffmanKathryn MortonSumati GuptaJulia BattenJared ThorleyJosiah HawksVictor Sacristan SantosGayatri NachaegariXuechen WangKenneth M BoucherBenjamin HaalandBenjamin L MaughanPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
BMMs declined significantly with combination therapy, and were associated with improved outcomes. Upon external validation, BMMs may emerge as surrogate markers to monitor treatment with radium-223 in real-time.